Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Conditions: Neuromyelitis Optica Spectrum Disorder Interventions: Other: Blood tests; Drug: Inebilizumab Sponsors: Horizon Therapeutics Ireland DAC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials